| Registry | NCT03234985, acronym NUCLARA |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 83 (Actual) |
| Sponsor | Hospices Civils de Lyon (Other) |
| Conditions | Acute Myeloid Leukemia |
| Interventions | Biological analyses (Biological) |
| Dates | start 2017-07-01, primary completion 2021-10-25, completion 2021-10-25, first posted 2017-08-01, last updated 2022-11-15 |
| Locations | 1 site in France |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Acute Myeloid Leukemia All trials of Biological analyses
Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and consolidation. Standard chemotherapy combination for induction treatment associates cytarabine (AraC), a nucleoside analog, and an anthracycline (most often daunorubucin). About 60-70% of patients achieved complete remission after this standard chemotherapy. As cytarabine competes with endogenous nucleotides to exert its activity, the aim of this protocol is to study in vivo the effect of intracellular nucleotide pools on the efficacy of the induction treatment. Thus, intracellular nucleotides levels will be determined in peripheral blood mononuclear cells of patients with acute myeloid leukemia before treatment, and results will be compared with the efficacy of the treatment. This parameter will be assessed by the achievement of complete remission.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| acute myeloid leukemia patients | Biological: Biological analyses | Patients over 18 years with acute myeloid leukemia |
Sex: All, ages: 18 Years to 65 Years, accepts healthy volunteers
Patients Inclusion Criteria: * age over 18 years * acute myeloid leukemia * standard induction chemotherapy with cytarabine and daunorubicin * patients who received the information and did not object to participate to the study Patients Exclusion Criteria: \- patients with acute myeloid leukemia 3 healthy volunteers Inclusion Criteria : * adults without known hematological disease, * adults who received the information and did not object to participate in the study healthy volunteers Exclusion Criteria : \- Volunteers with known hematological disease.
| Facility | City | Country | Status |
|---|---|---|---|
| Service d'hématologie - Centre Hospitalier Lyon Sud - Hospices Civils de LYON | Pierre-Bénite | France |